Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439413 · ClinicalTrials.gov registry record · Phase 2
Selegiline for Smoking Cessation - 1
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
NCT00439413 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 246 participants.
The verdict
NCT00439413, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
Study Summary
The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.
Interventions
- DRUG Placebo
- BEHAVIORAL Smoking Cessation Counseling
- DRUG Selegiline Transdermal Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439413
The ClinicalTrials.gov registry entry for NCT00439413 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00439413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00439413 about?
NCT00439413 is a clinical study titled "Selegiline for Smoking Cessation - 1". The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.
What is the current status of trial NCT00439413?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2007-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00439413?
The interventions under investigation include: Placebo (DRUG), Smoking Cessation Counseling (BEHAVIORAL), Selegiline Transdermal Patch (DRUG).
Who is sponsoring clinical trial NCT00439413?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.